Eun Jin Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eun Jin Kim has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Kyung Chan Kim
Daegu Catholic Univ, Med Ctr, Dept Internal Med, Sch Med, Daegu, South Korea
7 shared publications- Kyung Chan Kim
Department of Internal Medicine, Daegu Catholic University Hospital, Daegu, Korea
5 shared publications Keum-Ju Choi
Daegu Catholic Univ, Med Ctr, Dept Internal Med, Sch Med, Daegu, South Korea
4 shared publications- Hyo-Lim Hong
Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea
3 shared publications - Keum-Ju Choi
Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu Catholic University School of Medicine, Daegu, South Korea
3 shared publications - Eun Young Choi
Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam University and Regional Center for Respiratory Diseases, Yeungnam University Medical Center, Daegu, Korea
2 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (9) , 903
Antibiotic Escalation Following Rapid Multiplex PCR Pneumonia Panel Testing in Intensive Care Patients with Severe Pneumonia: A Retrospective Cohort Study
Background/Objectives: Severe community-acquired pneumonia (CAP) can be fatal and requires the rapid and appropriate administration of antibiotics. Rapid multiplex PCR pneumonia panels are widely used tools for antimicrobial de-escalation and stewardship; however, their role in driving antibiotic escalation in severe pneumonia requiring intensive care is less well characterized. Methods: We retrospectively analyzed 288 adults with severe CAP who were admitted to the intensive care unit (ICU) of a tertiary hospital and underwent lower-respiratory BioFire FilmArray Pneumonia Panel (BFPP) testing between April 2023 and September 2024. The primary outcome was antibiotic escalation, defined as addition of an agent or a change to broader-spectrum therapy after the BFPP result, and its associated factors. Secondary outcomes were in-hospital mortality, hospital and ICU length of stay (LOS), and ventilator duration according to the antibiotic escalation. Results: Patients were elderly (median 72 years old; 60.8% male) and critically ill (median SOFA 8; median APACHE-II 19; shock 49.0%; mechanical ventilation 56.9%). The panel was positive in 66.3% of cases, and results were obtained with a median turnaround time of 2 h versus 67 h for sputum culture. After the panel, antibiotics were escalated in 34.0% of cases, de-escalated in 2.8%, discontinued in 0.7%, and unchanged in 62.5%. Escalation was independently associated with resistance gene detection (adjusted odds ratio [aOR] 3.15, 95% CI 1.71–5.82), panel positivity (aOR 1.97, 95% CI 1.02–3.80), and SOFA score (aOR 1.10 per point, 95% CI 1.01–1.19). Thirty-day mortality, in-hospital mortality, hospital LOS, ICU LOS, and ventilator duration did not differ between escalation and non-escalation groups. Conclusions: In severe CAP requiring intensive care and managed with a comparatively narrow initial empirical regimen, panel testing was predominantly followed by antibiotic escalation rather than de-escalation, particularly when resistance genes were detected. No statistically measurable difference in clinical outcomes was observed, but the study was not powered to exclude any clinically meaningful benefit or harm of escalation.
- 14 September 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (9) , 903
Open AccessAntibiotic Escalation Following Rapid Multiplex PCR Pneumonia Panel Testing in Intensive Care Patients with Severe Pneumonia: A Retrospective Cohort Study
Background/Objectives: Severe community-acquired pneumonia (CAP) can be fatal and requires the rapid and appropriate administration of antibiotics. Rapid multiplex PCR pneumonia panels are widely used tools for antimicrobial de-escalation and stewardship; however, their role in driving antibiotic escalation in severe pneumonia requiring intensive care is less well characterized. Methods: We retrospectively analyzed 288 adults with severe CAP who were admitted to the intensive care unit (ICU) of a tertiary hospital and underwent lower-respiratory BioFire FilmArray Pneumonia Panel (BFPP) testing between April 2023 and September 2024. The primary outcome was antibiotic escalation, defined as addition of an agent or a change to broader-spectrum therapy after the BFPP result, and its associated factors. Secondary outcomes were in-hospital mortality, hospital and ICU length of stay (LOS), and ventilator duration according to the antibiotic escalation. Results: Patients were elderly (median 72 years old; 60.8% male) and critically ill (median SOFA 8; median APACHE-II 19; shock 49.0%; mechanical ventilation 56.9%). The panel was positive in 66.3% of cases, and results were obtained with a median turnaround time of 2 h versus 67 h for sputum culture. After the panel, antibiotics were escalated in 34.0% of cases, de-escalated in 2.8%, discontinued in 0.7%, and unchanged in 62.5%. Escalation was independently associated with resistance gene detection (adjusted odds ratio [aOR] 3.15, 95% CI 1.71–5.82), panel positivity (aOR 1.97, 95% CI 1.02–3.80), and SOFA score (aOR 1.10 per point, 95% CI 1.01–1.19). Thirty-day mortality, in-hospital mortality, hospital LOS, ICU LOS, and ventilator duration did not differ between escalation and non-escalation groups. Conclusions: In severe CAP requiring intensive care and managed with a comparatively narrow initial empirical regimen, panel testing was predominantly followed by antibiotic escalation rather than de-escalation, particularly when resistance genes were detected. No statistically measurable difference in clinical outcomes was observed, but the study was not powered to exclude any clinically meaningful benefit or harm of escalation.
- Open Access
- 6 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (4)
Surgical lung biopsy analyses differ by race and ethnicity in interstitial lung disease
Aim: Establishing an interstitial lung disease (ILD) diagnosis may require surgical lung biopsy (SLB). While prior studies have described the epidemiology of ILDs among different races and ethnicities, the pathological and clinical diagnoses based on SLBs associated with these demographics are unexplored. Methods: We reviewed SLBs performed between 2000 and 2022 at the University of California San Francisco (UCSF) and the University of Chicago (UChicago) assessing histopathology using structured data collection forms. We analysed differences in histopathological features among White, Black, Asian, Hispanic and Native American participants. Results: A total of 1100 patients (899 UCSF and 201 UChicago study subjects, respectively) with chronic ILD underwent SLBs. 80.6% of patients were White, 6.7% Black, 5.7% Asian, 5% Hispanic and 1.9% Native American. The mean age was 61 years, with Black participants being younger (53 years). Notable histopathological differences include higher frequency of germinal centre formation in Black participants who also had less microscopic honeycombing, and less frequency of organising pneumonia in Hispanic participants. Hispanic participants had pathological nonspecific interstitial pneumonia (NSIP) whereas Native American participants mostly had fibrosing interstitial pneumonia. Hypersensitivity pneumonitis (HP) was the most common clinical diagnosis in White and Hispanic participants, connective tissue disease-ILD in Black participants and unclassifiable ILD in Native American participants. HP and NSIP frequently require SLB. Conclusions: This study demonstrates significant racial and ethnic differences in pathological and clinical diagnoses among ILDs. Recognising these differences is critical for tailoring diagnostic approaches and may impact precision medicine approaches for ILD management.
- 6 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (4)
Open AccessSurgical lung biopsy analyses differ by race and ethnicity in interstitial lung disease
Aim: Establishing an interstitial lung disease (ILD) diagnosis may require surgical lung biopsy (SLB). While prior studies have described the epidemiology of ILDs among different races and ethnicities, the pathological and clinical diagnoses based on SLBs associated with these demographics are unexplored. Methods: We reviewed SLBs performed between 2000 and 2022 at the University of California San Francisco (UCSF) and the University of Chicago (UChicago) assessing histopathology using structured data collection forms. We analysed differences in histopathological features among White, Black, Asian, Hispanic and Native American participants. Results: A total of 1100 patients (899 UCSF and 201 UChicago study subjects, respectively) with chronic ILD underwent SLBs. 80.6% of patients were White, 6.7% Black, 5.7% Asian, 5% Hispanic and 1.9% Native American. The mean age was 61 years, with Black participants being younger (53 years). Notable histopathological differences include higher frequency of germinal centre formation in Black participants who also had less microscopic honeycombing, and less frequency of organising pneumonia in Hispanic participants. Hispanic participants had pathological nonspecific interstitial pneumonia (NSIP) whereas Native American participants mostly had fibrosing interstitial pneumonia. Hypersensitivity pneumonitis (HP) was the most common clinical diagnosis in White and Hispanic participants, connective tissue disease-ILD in Black participants and unclassifiable ILD in Native American participants. HP and NSIP frequently require SLB. Conclusions: This study demonstrates significant racial and ethnic differences in pathological and clinical diagnoses among ILDs. Recognising these differences is critical for tailoring diagnostic approaches and may impact precision medicine approaches for ILD management.
- Open Access
- 5 June 2023
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 46, 101885
A case of granulocyte colony-stimulating factor producing lung adenocarcinoma with anaplastic lymphoma kinase gene rearrangements
- 5 June 2023
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 46, 101885
Open AccessA case of granulocyte colony-stimulating factor producing lung adenocarcinoma with anaplastic lymphoma kinase gene rearrangements
- Open Access
- 31 May 2023
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 38 (2) , 249
Corrigendum to “Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study”
- 31 May 2023
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 38 (2) , 249
Open AccessCorrigendum to “Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study”
- Open Access
- 28 February 2023
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 38 (1) , 57-67
Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study
Background: The guidelines recommend the use of dexamethasone 6 mg or an equivalent dose in patients with coronavirus disease 2019 (COVID-19) who require supplemental oxygen. Given that the severity of COVID-19 varies, we investigated the effect of a pulse dose of corticosteroids on the clinical course of critically ill patients with COVID-19.Methods: This single-center, retrospective cohort study was conducted between September and December 2021, which was when the Delta variant of the COVID-19 virus was predominant. We evaluated the mortality and oxygenation of severe to critical COVID-19 cases between groups that received dexamethasone 6 mg for 10 days (control group) and methylprednisolone 250 mg/day for 3 days (pulse group).Results: Among 44 patients, 14 and 30 patients were treated with control steroids and pulse steroids, respectively. There was no difference in disease severity, time from COVID-19 diagnosis to steroid administration, or use of remdesivir or antibacterial agents between the two groups. The pulse steroid group showed a significant improvement in oxygenation before and after steroid treatment (P<0.001) compared with the control steroid group (P=0.196). There was no difference in in-hospital mortality (P=0.186); however, the pulse steroid group had a lower mortality rate (23.3%) than the control steroid group (42.9%). There was a significant difference in the length of hospital stay between both two groups (P=0.039). Conclusions: Pulse steroids showed no mortality benefit but were associated with oxygenation improvement and shorter hospital stay than control steroids. Hyperglycemia should be carefully monitored with pulse steroids.
- 28 February 2023
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 38 (1) , 57-67
Open AccessMethylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study
Background: The guidelines recommend the use of dexamethasone 6 mg or an equivalent dose in patients with coronavirus disease 2019 (COVID-19) who require supplemental oxygen. Given that the severity of COVID-19 varies, we investigated the effect of a pulse dose of corticosteroids on the clinical course of critically ill patients with COVID-19.Methods: This single-center, retrospective cohort study was conducted between September and December 2021, which was when the Delta variant of the COVID-19 virus was predominant. We evaluated the mortality and oxygenation of severe to critical COVID-19 cases between groups that received dexamethasone 6 mg for 10 days (control group) and methylprednisolone 250 mg/day for 3 days (pulse group).Results: Among 44 patients, 14 and 30 patients were treated with control steroids and pulse steroids, respectively. There was no difference in disease severity, time from COVID-19 diagnosis to steroid administration, or use of remdesivir or antibacterial agents between the two groups. The pulse steroid group showed a significant improvement in oxygenation before and after steroid treatment (P<0.001) compared with the control steroid group (P=0.196). There was no difference in in-hospital mortality (P=0.186); however, the pulse steroid group had a lower mortality rate (23.3%) than the control steroid group (42.9%). There was a significant difference in the length of hospital stay between both two groups (P=0.039). Conclusions: Pulse steroids showed no mortality benefit but were associated with oxygenation improvement and shorter hospital stay than control steroids. Hyperglycemia should be carefully monitored with pulse steroids.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (19) , e141
The Profile of Early Sedation Depth and Clinical Outcomes of Mechanically Ventilated Patients in Korea
Hyun DG, et al. J Korean Med Sci. 2023 Apr;38(19):e141. https://doi.org/10.3346/jkms.2023.38.e141
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (19) , e141
Open AccessThe Profile of Early Sedation Depth and Clinical Outcomes of Mechanically Ventilated Patients in Korea
Hyun DG, et al. J Korean Med Sci. 2023 Apr;38(19):e141. https://doi.org/10.3346/jkms.2023.38.e141
- Open Access
- 1 January 2023
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 16, 189-200
Epidemiology and Mortality Analysis Related to Carbapenem-Resistant Enterobacterales in Patients After Admission to Intensive Care Units: An Observational Study
Purpose: The prevalence of carbapenem-resistant Enterobacterales (CRE) is rapidly increasing worldwide. Patients in the intensive care unit (ICU) are susceptible to CRE infections, and the related mortality rate is increased. It is necessary to understand CRE strains and risk factors for CRE infection in the ICU, to facilitate development of effective prophylactic strategies and treatments for ICU patients. Patients and Methods: This observational study was conducted in a tertiary hospital between 2016 and 2021. The subjects were patients with CRE cultured from specimens obtained after ICU admission. Genotypes of strains of CRE and carbapenemase-producing Enterobacterales (CPE) were identified, CRE infection was distinguished from mere colonization, and the clinical course of these patients was investigated. Results: Among 327 CRE cases, 84 (25.7%) showed infection and 243 (74.3%) showed colonization. Of these patients, 138 (42.2%) died. The CRE strains were Klebsiella pneumoniae (253 cases, 77.4%), Enterobacter cloacae (44 cases, 13.5%), and Escherichia coli (15 cases, 4.6%). Among CRE cases, CPE was found in 249 (76.1%), including Klebsiella pneumoniae carbapenemase (KPC) in 164 (65.9%), and Guiana extended-spectrum (GES) in 64 (25.7%). A bedridden state, longer ICU stay, chronic kidney disease, malignancy, connective tissue disease, ICU admission for cardiac arrest, and CRE infection were associated with higher mortality, but cerebrovascular disease and ICU admission for trauma were associated with lower mortality. GES outbreak was caused by person-to-person transmission and was controlled through active surveillance. Conclusion: The frequency of K. pneumoniae and KPC was the highest, but E. cloacae and GES was characteristically high in this study. Active CRE surveillance can be helpful for controlling outbreak.
- 1 January 2023
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 16, 189-200
Open AccessEpidemiology and Mortality Analysis Related to Carbapenem-Resistant Enterobacterales in Patients After Admission to Intensive Care Units: An Observational Study
Purpose: The prevalence of carbapenem-resistant Enterobacterales (CRE) is rapidly increasing worldwide. Patients in the intensive care unit (ICU) are susceptible to CRE infections, and the related mortality rate is increased. It is necessary to understand CRE strains and risk factors for CRE infection in the ICU, to facilitate development of effective prophylactic strategies and treatments for ICU patients. Patients and Methods: This observational study was conducted in a tertiary hospital between 2016 and 2021. The subjects were patients with CRE cultured from specimens obtained after ICU admission. Genotypes of strains of CRE and carbapenemase-producing Enterobacterales (CPE) were identified, CRE infection was distinguished from mere colonization, and the clinical course of these patients was investigated. Results: Among 327 CRE cases, 84 (25.7%) showed infection and 243 (74.3%) showed colonization. Of these patients, 138 (42.2%) died. The CRE strains were Klebsiella pneumoniae (253 cases, 77.4%), Enterobacter cloacae (44 cases, 13.5%), and Escherichia coli (15 cases, 4.6%). Among CRE cases, CPE was found in 249 (76.1%), including Klebsiella pneumoniae carbapenemase (KPC) in 164 (65.9%), and Guiana extended-spectrum (GES) in 64 (25.7%). A bedridden state, longer ICU stay, chronic kidney disease, malignancy, connective tissue disease, ICU admission for cardiac arrest, and CRE infection were associated with higher mortality, but cerebrovascular disease and ICU admission for trauma were associated with lower mortality. GES outbreak was caused by person-to-person transmission and was controlled through active surveillance. Conclusion: The frequency of K. pneumoniae and KPC was the highest, but E. cloacae and GES was characteristically high in this study. Active CRE surveillance can be helpful for controlling outbreak.
- Open Access
- 31 December 2022
- Published by The Korean Geriatrics Society in Annals of Geriatric Medicine and Research
- Vol. 26 (4) , 367-371
Herpes Simplex Virus Type 1 with Concomitant Pneumonia and Urinary Tract Infection in an Older Patient: A Case Report
A 76-year-old female patient was unable to ambulate due to sequelae of cerebrovascular disease and had been living in a healthcare facility. On admission, the patient was diagnosed with sepsis and a urinary tract infection caused by Candida tropicalis. Chest radiography showed right lung atelectasis, while bronchoscopy showed bronchial stenosis with anthracotic pigmentation in both bronchi. Bronchial washing cytology revealed herpes simplex virus (HSV) type 1-infected cells with intranuclear inclusions and multinucleation on the 7th day. Moreover, the patient showed microscopic hematuria. Urine cytology also revealed HSV type 1-infected cells. The patient was treated with antiviral (acyclovir), antifungal, and antibiotic agents. One week later, follow-up urine cytology revealed the absence of HSV infection, and her condition was stabilized. However, her clinical condition deteriorated due to an infection caused by multidrug-resistant bacterial pathogens, and she eventually died 4 weeks after admission. We describe a case of HSV type 1 pneumonia and urinary tract infection in an older adult patient.
- 31 December 2022
- Published by The Korean Geriatrics Society in Annals of Geriatric Medicine and Research
- Vol. 26 (4) , 367-371
Open AccessHerpes Simplex Virus Type 1 with Concomitant Pneumonia and Urinary Tract Infection in an Older Patient: A Case Report
A 76-year-old female patient was unable to ambulate due to sequelae of cerebrovascular disease and had been living in a healthcare facility. On admission, the patient was diagnosed with sepsis and a urinary tract infection caused by Candida tropicalis. Chest radiography showed right lung atelectasis, while bronchoscopy showed bronchial stenosis with anthracotic pigmentation in both bronchi. Bronchial washing cytology revealed herpes simplex virus (HSV) type 1-infected cells with intranuclear inclusions and multinucleation on the 7th day. Moreover, the patient showed microscopic hematuria. Urine cytology also revealed HSV type 1-infected cells. The patient was treated with antiviral (acyclovir), antifungal, and antibiotic agents. One week later, follow-up urine cytology revealed the absence of HSV infection, and her condition was stabilized. However, her clinical condition deteriorated due to an infection caused by multidrug-resistant bacterial pathogens, and she eventually died 4 weeks after admission. We describe a case of HSV type 1 pneumonia and urinary tract infection in an older adult patient.
- Open Access
- 28 April 2022
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 22 (1) , 1
Correction to: Pulmonary tuberculosis presenting secondary organizing pneumonia with organized polypoid granulation tissue: case series and review of the literature
- 28 April 2022
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 22 (1) , 1
Open AccessCorrection to: Pulmonary tuberculosis presenting secondary organizing pneumonia with organized polypoid granulation tissue: case series and review of the literature
- Open Access
- 29 October 2021
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 21 (1) , 1-10
Comparison of clinical features and prognosis in patients with cryptogenic and secondary organizing pneumonia
Background: Organizing pneumonia (OP) can be diagnosed pathologically, and cryptogenic OP (COP) and secondary OP (SOP) have been classified by cause and particular underlying context. Because it is clinically difficult to differentiate between COP and SOP, this study investigated characteristics that could distinguish between COP and SOP. Methods: The medical records of patients who underwent lung biopsy for a diagnosis of OP at a single tertiary hospital from January 2016 to December 2018 were retrospectively reviewed. Results: Eighty-five patients had pathologically proven OP, including 16 diagnosed with COP and 69 diagnosed with SOP. The most common cause of SOP was infectious pneumonia, observed in 57 (82.6%) of the 69 patients, followed by cancer and radiation pneumonitis. The pathogens causing infectious pneumonia were identified in 45 (65.2%) patients. There were no differences in age, sex, and lung function between the COP and SOP groups. Median body mass index was significantly lower (P = 0.030), and median time from symptom onset to hospital admission significantly shorter (P = 0.006), in the SOP than in the COP group. Fever was more common in the SOP group (P = 0.024), and CURB 65, an index of pneumonia severity, tended to be higher in the SOP group (P = 0.017). Some laboratory results differed significantly between the two groups. Lymphocyte counts in bronchoalveolar lavage (BAL) fluid were significantly higher in the COP than in the SOP group (P = 0.012). Radiologic findings showed that effusion was more common in the SOP group (P = 0.036). There were no between-group differences in steroid use, 30 day and in-hospital mortality rates, and rates of OP outcomes and recurrences. Pneumonia recurrence rate was significantly higher in SOP patients who were than were not treated with steroids (P = 0.035). Conclusions: Infection is the main cause of SOP. Symptom onset is more rapid in patients with SOP than with COP. Some blood and BAL fluid test results differed significantly in the COP and SOP groups. Pleural effusion was more common in the SOP group but there were no differences in clinical course. Recurrence in patients with SOP was more common in those who were than were not treated with steroids.
- 29 October 2021
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 21 (1) , 1-10
Open AccessComparison of clinical features and prognosis in patients with cryptogenic and secondary organizing pneumonia
Background: Organizing pneumonia (OP) can be diagnosed pathologically, and cryptogenic OP (COP) and secondary OP (SOP) have been classified by cause and particular underlying context. Because it is clinically difficult to differentiate between COP and SOP, this study investigated characteristics that could distinguish between COP and SOP. Methods: The medical records of patients who underwent lung biopsy for a diagnosis of OP at a single tertiary hospital from January 2016 to December 2018 were retrospectively reviewed. Results: Eighty-five patients had pathologically proven OP, including 16 diagnosed with COP and 69 diagnosed with SOP. The most common cause of SOP was infectious pneumonia, observed in 57 (82.6%) of the 69 patients, followed by cancer and radiation pneumonitis. The pathogens causing infectious pneumonia were identified in 45 (65.2%) patients. There were no differences in age, sex, and lung function between the COP and SOP groups. Median body mass index was significantly lower (P = 0.030), and median time from symptom onset to hospital admission significantly shorter (P = 0.006), in the SOP than in the COP group. Fever was more common in the SOP group (P = 0.024), and CURB 65, an index of pneumonia severity, tended to be higher in the SOP group (P = 0.017). Some laboratory results differed significantly between the two groups. Lymphocyte counts in bronchoalveolar lavage (BAL) fluid were significantly higher in the COP than in the SOP group (P = 0.012). Radiologic findings showed that effusion was more common in the SOP group (P = 0.036). There were no between-group differences in steroid use, 30 day and in-hospital mortality rates, and rates of OP outcomes and recurrences. Pneumonia recurrence rate was significantly higher in SOP patients who were than were not treated with steroids (P = 0.035). Conclusions: Infection is the main cause of SOP. Symptom onset is more rapid in patients with SOP than with COP. Some blood and BAL fluid test results differed significantly in the COP and SOP groups. Pleural effusion was more common in the SOP group but there were no differences in clinical course. Recurrence in patients with SOP was more common in those who were than were not treated with steroids.